Destiny Pharma plc (LON:DEST – Get Free Report)’s share price was up 11.1% on Tuesday . The company traded as high as GBX 3.94 ($0.05) and last traded at GBX 3.89 ($0.05). Approximately 1,222,156 shares were traded during trading, an increase of 123% from the average daily volume of 547,344 shares. The stock had previously closed at GBX 3.50 ($0.05).
Analysts Set New Price Targets
Separately, Shore Capital reaffirmed a “house stock” rating on shares of Destiny Pharma in a report on Monday, July 15th.
Get Our Latest Stock Analysis on DEST
Destiny Pharma Stock Performance
Destiny Pharma Company Profile
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
Read More
- Five stocks we like better than Destiny Pharma
- What Are Dividends? Buy the Best Dividend Stocks
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- Financial Services Stocks Investing
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- What is the Nikkei 225 index?
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.